LAWRENCE, Mass., Jan. 9, 2012 /PRNewswire/ — NxStage Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that its Medisystems in-center business and B. Braun Medical Inc. have agreed to extend their supply agreement under which Medisystems will supply B. Braun with its Streamline® blood tubing sets for use on the B. Braun Dialog® and Dialog+® hemodialysis systems, Medisystems MasterGuard® and Buttonhole® needles, and ancillary products for sale in the U.S. Under the terms of the amended agreement, which has been extended through 2014, B. Braun will provide sales, marketing and clinical support to its customers in the U.S.
(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )
Medisystems‘ Streamline technology has fast become our standard bloodline product, with our customers reporting improved operational efficiencies, said Sam Amory, Vice President B. Braun Renal Therapies Division. We are pleased to provide Streamline as well as Medisystems MasterGuard and Buttonhole needles and ancillary products so our customers can provide excellent dialysis care.
Streamline features an efficient and airless design intended to improve clinical and economic performance. Streamline is designed to reduce dialysate flow, dialyzer size, treatment time, minimize heparin and waste, and optimize dose delivery, as measured in Kt/V. Streamline also includes NxStage’s patented LockSite® needleless access ports, which eliminates the need for sharp needles or costlier guarded needles to be used with the tubing set during dialysis.
This agreement validates the excellent performance of Medisystems‘ Streamline blood tubing sets and demonstrates our continued commitment to provide B. Braun customers with market leading products, said Mark Florence, Vice President and General Manager, Medisystems. We look forward to working with B. Braun to meet the growing demand for Streamline.
About B. Braun Renal Therapies Division
B. Braun has been a leader in providing the dialysis community with innovative products for over 35 years. The Dialog+® hemodialysis system incorporates the most advanced state-of-the art technology in dialysis. As a manufacturer and distributor of hemodialysis equipment and related disposables, including the Diacap @ Polysulfone® dialyzers, the Renal Therapies Division of B. Braun is committed to the continued development of high quality products for hemodialysis and continuous renal replacement therapy supported by a team of clinical nurses, field service personnel, customer service and 24/7 technical assistance. For more information, call 800-848-2066, e-mail B. Braun at email@example.com or visit B. Braun at www.bbraunusa.com .
About NxStage Medical
NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company’s website at http://www.nxstage.com/.
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words anticipate, believe, expect, estimate, plan, and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage’s filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2011. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.
Kristen Sheppard, Esq.
Vice President, Investor Relations
NxStage Medical, Inc.
SOURCE NxStage Medical, Inc.